Skip to content

About the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center

In This Video

  • Justin Gainor, MD, is the director of the Center for Thoracic Cancers and the director of Targeted Immunotherapy at the Massachusetts General Hospital Cancer Center
  • He explains what the Henri and Belinda Termeer Center is and why it is important
  • The Termeer Center is where phase I clinical trials of novel targeted therapies or novel immunotherapies are conducted and where investigators from the entire Cancer Center come together to study and perform these early phase studies

Justin Gainor, MD, is the director of the Center for Thoracic Cancers and the director of Targeted Immunotherapy at Massachusetts General Hospital Cancer Center. In this video, he explains the importance of the Cancer Center's Henri and Belinda Termeer Center and what it is.

Transcript

The Termeer Center at Massachusetts General Hospital is both a physical space and an intellectual space. It is a physical space in the sense that this is really where our early phase drug development is done, so these are generally phase I clinical trials of novel targeted therapies or novel immunotherapies and it's really a space where investigators from the entire cancer center come together to study and perform these early phase studies. I mentioned it is also an intellectual space because we now have 18 Termeer investigators who are part of the Termeer Center, and they come from all different facets of the Cancer Center so every disease center is represented. It's really a group of investigators dedicated to advancing cancer care. And this means brainstorming ideas, thinking about translational research together, and it really serving as a hub for translational research as well as research connected with our basic scientists. So in that sense, it really is a community of investigation.

Massachusetts General Hospital is a very special place. It's a very special place because it really brings together clinicians like myself, along with basic scientists, and really that's where the advances in cancer care are going to come. It's going to come from multiple different types of investigators working together, not in silos, and I think Massachusetts General Hospital is one of those special places that really facilitate the cross-fertilization of ideas.

Visit the Henri and Belinda Termeer Center

Refer a patient to the Mass General Cancer Center

Related

Research conducted by Dr. Adam Feldman, Dr. Leo Cheng, and colleagues shows promising results for a non-invasive technique detecting metabolic signature between benign and cancerous prostate tissue.

Related

Matthew R. Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, and colleagues demonstrated in a worldwide phase 3 trial in patients with nonmetastatic, castration-resistant prostate cancer that darolutamide reduced the risk of metastasis or death from any cause by 59%.